Cargando…
Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19
Autores principales: | Núñez-Torrón, Claudia, García-Gutiérrez, Valentín, Tenorio-Núñez, María Concepción, Moreno-Jiménez, Gemma, López-Jiménez, Francisco Javier, Herrera-Puente, Pilar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270740/ https://www.ncbi.nlm.nih.gov/pubmed/32499538 http://dx.doi.org/10.1038/s41409-020-0961-y |
Ejemplares similares
-
The impact of lockdown during the COVID-19 pandemic on newly acute myeloid leukemia patients: Single-centre comparative study between 2019 and 2020 cohorts in Madrid
por: Martín-Moro, Fernando, et al.
Publicado: (2021) -
Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience
por: Roldán Pérez, Alicia, et al.
Publicado: (2022) -
Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera
por: Piris-Villaespesa, Miguel, et al.
Publicado: (2021) -
It takes two to bleed: anticoagulation intensity and the host’s vascular susceptibility. Author’s reply
por: Nunez, Jose I., et al.
Publicado: (2022) -
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
por: Garcia-Gutiérrez, Valentín, et al.
Publicado: (2021)